- Home
- GOSS vs DHY Comparison
GOSS vs DHY Comparison
Compare GOSS & DHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- DHY
- Stock Information
- Founded
- GOSS 2015
- DHY 1998
- Country
- GOSS United States
- DHY United States
- Employees
- GOSS N/A
- DHY N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- DHY Finance/Investors Services
- Sector
- GOSS Health Care
- DHY Finance
- Exchange
- GOSS Nasdaq
- DHY Nasdaq
- Market Cap
- GOSS 203.3M
- DHY 212.4M
- IPO Year
- GOSS 2019
- DHY N/A
- Fundamental
- Price
- GOSS $1.17
- DHY $2.05
- Analyst Decision
- GOSS Strong Buy
- DHY
- Analyst Count
- GOSS 4
- DHY 0
- Target Price
- GOSS $7.75
- DHY N/A
- AVG Volume (30 Days)
- GOSS 1.6M
- DHY 569.1K
- Earning Date
- GOSS 05-15-2025
- DHY 01-01-0001
- Dividend Yield
- GOSS N/A
- DHY 9.10%
- EPS Growth
- GOSS N/A
- DHY N/A
- EPS
- GOSS N/A
- DHY N/A
- Revenue
- GOSS $124,590,000.00
- DHY N/A
- Revenue This Year
- GOSS N/A
- DHY N/A
- Revenue Next Year
- GOSS $190.37
- DHY N/A
- P/E Ratio
- GOSS N/A
- DHY N/A
- Revenue Growth
- GOSS N/A
- DHY N/A
- 52 Week Low
- GOSS $0.50
- DHY $1.77
- 52 Week High
- GOSS $1.55
- DHY $2.08
- Technical
- Relative Strength Index (RSI)
- GOSS 55.35
- DHY 53.01
- Support Level
- GOSS $1.09
- DHY $1.92
- Resistance Level
- GOSS $1.20
- DHY $2.00
- Average True Range (ATR)
- GOSS 0.09
- DHY 0.02
- MACD
- GOSS 0.00
- DHY 0.00
- Stochastic Oscillator
- GOSS 69.01
- DHY 60.00
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About DHY Credit Suisse High Yield Bond Fund
Credit Suisse High Yield Bond Fund is a non-diversified, closed-end management investment company to seeks high current income and capital appreciation as a secondary objective.